BioRem Inc.
BRM.V · TSXV
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.01 | -3.45 | -0.78 |
| FCF Yield | 2.87% | -4.43% | 11.06% | -3.44% |
| EV / EBITDA | 14.95 | 26.85 | 154.85 | 111.51 |
| Quality | ||||
| ROIC | 7.76% | 5.50% | 0.49% | 1.44% |
| Gross Margin | 28.13% | 27.04% | 23.46% | 17.15% |
| Cash Conversion Ratio | 0.78 | -1.79 | 126.33 | -9.90 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.31% | 14.33% | 9.43% | 9.04% |
| Free Cash Flow Growth | 156.88% | -134.43% | 371.64% | -154.77% |
| Safety | ||||
| Net Debt / EBITDA | -3.02 | -3.88 | -27.26 | -3.88 |
| Interest Coverage | 42.01 | 25.99 | 2.16 | 6.11 |
| Efficiency | ||||
| Inventory Turnover | 3.91 | 3.81 | 1.10 | 2.66 |
| Cash Conversion Cycle | 74.82 | 98.44 | 189.37 | 130.62 |